Immunic, Inc. has announced the release of new, positive long-term data from the open-label extension (OLE) of its phase 2 EMPhASIS trial, focusing on the lead asset vidofludimus calcium (IMU-838) in patients with relapsing-remitting multiple sclerosis (RRMS). The data, available for up to 5.5 years, highlights that at Week 144, 92.3% of patients remained free of 12-week confirmed disability worsening $(CDW)$, and 92.7% remained free of 24-week CDW. The trial results, already presented, indicate a favorable safety and tolerability profile for vidofludimus calcium, with low discontinuation rates and low rates of treatment-emergent and serious adverse events. No new safety signals have been reported, underscoring the potential of vidofludimus calcium in managing RRMS.